Search the Newsreel

Goosehead Insurance, Inc. Class A Revenue Breakdown – SWB:2OX

This article provides a revenue breakdown for Goosehead Insurance, Inc. Class A (SWB:2OX). It highlights that the company generated 311.03 million EUR last year, primarily from its Insurance Distribution segment. The United States was the greatest contributor to its revenue.

Arrowhead Pharmaceuticals, Inc. Revenue Breakdown – XETR:HDP1

Arrowhead Pharmaceuticals Inc. (XETR:HDP1) reported a total revenue of €706.85 million last year, primarily driven by its RNA Interference Therapeutics segment. The United States was the leading geographical contributor, generating the entirety of this revenue. This marks a significant increase from €3.19 million in …

Headlam Group plc Revenue Breakdown – LSE:HEAD

Goosehead Insurance Stock: Solid Q2, But Longer-Term AI Risks Linger (NASDAQ:GSHD)

Headwater Exploration: Adjusting Production Guidance Upwards (OTCMKTS:CDDRF)

Goosehead Insurance: Strong Q2, But The Valuation Leaves Little Room For Error (NASDAQ:GSHD)

Why (BOW) Price Action Is Critical for Tactical Trading

This article analyzes Bowhead Specialty Holdings Inc. (BOW) using AI-generated signals for tactical trading. It highlights weak near and mid-term sentiment, a neutral long-term outlook, and identifies a significant short setup with an exceptional risk-reward ratio. The analysis provides specific trading strategies including position, …

Is Arrowhead Pharmaceuticals Stock A Smart Buy After Its Transition To A Commercial Company?

Arrowhead Pharmaceuticals (ARWR) has transitioned into a commercial company with its first approved drug, REDEMPLO, and a strong pipeline. While the stock has seen significant growth and has a high valuation, indicating market belief in future potential, its history shows high volatility and deep …

Goosehead Insurance (GSHD) Stock Faces Premium P/E As 8.8% Net Margin Tests Bullish Narrative

Morgan Stanley Forecasts Strong Price Appreciation for Arrowhead Pharmaceuticals (NASDAQ:ARWR) Stock

Goosehead Insurance (NASDAQ:GSHD) Trading Up 6.5% on Better-Than-Expected Earnings

Arrowhead Pharmaceuticals (ARWR) Hits 52-Week High Following Pos

Arrowhead Pharmaceuticals (ARWR) reached a new 52-week high after reporting successful late-stage trial results for its lipid-lowering drug, plozasiran, which showed an 81% median triglyceride reduction. Despite the positive news and a significant market cap of $13.02 billion, the company holds a low GF …

Arrowhead Pharmaceuticals Inc Stock (ARWR) Closed Up by 19.04% on Jul 22: What Signal Does It Send?

Arrowhead Pharmaceuticals Inc. (ARWR) stock rose 19.04% on July 22, driven by positive Phase 3 clinical trial results for its RNA interference candidate in cardiometabolic disorders. Despite the strong fundamental news and analyst price target increases, technical indicators like MACD and Williams %R suggest …

Goosehead places $1.34B in premiums; policies in force grow 15%

Goosehead Insurance (NASDAQ:GSHD) announced strong second-quarter 2026 results, with total revenues increasing 21% year-over-year to $113.4 million and net income rising to $17.0 million. The company's total written premiums grew 14% to $1.34 billion, and policies in force increased 15% to approximately 2.1 million, …

Goosehead Insurance, Inc. Announces Second Quarter 2026 Results

Goosehead Insurance, Inc. (NASDAQ: GSHD) announced strong second-quarter 2026 results, with total revenue increasing 21% to $113.4 million and net income rising to $17.0 million from $8.3 million a year ago. The company demonstrated significant growth in policies in force and increased its full-year …

Arrowhead (ARWR) Soars to New High as Plozasiran Nears Expanded Commercialization

Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) skyrocketed to a five-year high on Wednesday, as investors began positioning portfolios ahead of the supplemental new drug application (sNDA) of its drug candidate, plozasiran, for the treatment of severe hypertriglyceridemia. In intra-day trading, the stock soared by as much …

Arrowhead Drug Shows Strong Efficacy In Cutting Blood Fat

Arrowhead Pharmaceuticals' (NASDAQ: ARWR) drug plozasiran has shown strong efficacy in reducing triglyceride levels and acute pancreatitis occurrences in patients with severe hypertriglyceridemia across two Phase 3 trials, SHASTA-3 and SHASTA-4. Patients receiving 25 mg quarterly saw significant reductions in triglyceride levels, and high-risk …

Top Midday Gainers

Arrowhead Pharmaceuticals (ARWR) said Wednesday topline results from its global phase 3 clinical stu PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade Already have a …

Arrowhead Pharmaceuticals (ARWR) Stock Looks Fairly Priced With Strong Sales But A Demanding 398% Run

Arrowhead Pharmaceuticals has seen an extreme 398.1% gain over the past year, leading to a valuation that is now considered fairly priced rather than an obvious bargain. While the recent European Commission authorization for Redemplo supports higher revenue expectations, clinical and reimbursement uncertainties for …

Arrowhead Pharmaceuticals Reports Topline Results from Phase 3 SHASTA-3 and SHASTA-4 Studies of Plozasiran in Patients with Severe Hypertriglyceridemia

Arrowhead Pharmaceuticals announced positive topline results from its Phase 3 SHASTA-3 and SHASTA-4 clinical studies of plozasiran for severe hypertriglyceridemia (sHTG). The drug achieved deep and consistent triglyceride reductions of 79% and 81%, respectively, and statistically significant reductions in acute pancreatitis events, including a …

Why Arrowhead Pharmaceuticals Is Surging 24.4%: JP Morgan Maintains Overweight

Arrowhead Pharmaceuticals (ARWR) surged 24.4% to $92.72 after JP Morgan upgraded the biotech's rating to Overweight and raised its price target from $88 to $95. This upgrade was attributed to positive regulatory signals from the FDA, energizing investor interest in the RNAi therapeutics developer. …

ARWR Jumps As REDEMPLO Win Fuels Bullish Targets

Arrowhead Pharmaceuticals Inc. (ARWR) stock jumped over 22% after European regulators approved its drug REDEMPLO for familial chylomicronemia syndrome, backed by strong Phase 3 data. This approval, combined with bullish analyst targets from Stifel and JPMorgan anticipating a $3B market for upcoming severe hypertriglyceridemia …

Ionis drops as Arrowhead posts late-stage trial win for lipid-lowering drug

Arrowhead Pharmaceuticals announced positive late-stage trial results for its lipid-lowering drug, plozasiran, intended for patients with severe hypertriglyceridemia. This news negatively impacted Ionis Pharmaceuticals, a competitor in the same therapeutic area. An earlier version of the story was corrected to reflect that Ionis Pharma's …

Arrowhead Pharmaceuticals shares surge after positive Phase 3 results for plozasiran (NASDAQ:ARWR)

Arrowhead Pharmaceuticals (NASDAQ:ARWR) saw its shares jump 18% after announcing positive topline data from its Phase 3 SHASTA-3 and SHASTA-4 clinical trials for plozasiran. The trials successfully met all primary and secondary endpoints, showing significant reductions in triglyceride levels and a favorable safety profile …

ARWR: SHASTA-3 and SHASTA-4 Hit on All Endpoints Including 100% Reduction in Acute Pancreatitis in High-Risk Patients

By David Bautz, PhD NASDAQ: ARWR READ THE FULL ARWR RESEARCH REPORT Business Update Best Case Scenario for SHASTA-3 and SHASTA-4 Results On July 22, 2026, Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) announced positive topline results for the SHASTA-3 and SHASTA-4 trials of plozasiran in patients …

Goosehead (GSHD) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates

Goosehead Insurance Q2 Earnings Call Highlights

GOOSEHEAD INSURANCE ($GSHD) Releases Q2 2026 Earnings, Stock Rises

Goosehead Insurance (NASDAQ:GSHD) Posts Earnings Results, Beats Expectations By $0.17 EPS

Goosehead Insurance (GSHD) Q2 Earnings and Revenues Beat Estimates

Arrowhead: Stock Up On SHTG Data - No Ceiling On Valuation Growth Potential (NASDAQ:ARWR)

Arrowhead Pharmaceuticals to Webcast Fiscal 2026 Third Quarter Results

Arrowhead Pharmaceuticals announced it will host a webcast and conference call on August 4, 2026, at 4:30 p.m. ET to discuss its financial results for the fiscal 2026 third quarter, which ended June 30, 2026. Investors can access the live audio webcast and its …

Bowhead Specialty (NYSE:BOW) Given New $33.00 Price Target at JPMorgan Chase & Co.

JPMorgan Chase & Co. has raised its price target for Bowhead Specialty (NYSE:BOW) from $30.00 to $33.00, maintaining a "neutral" rating on the stock. This new target implies a potential upside of 7.06% from its previous close. Other analysts have also adjusted their targets …

Goosehead Insurance, Inc. to Host Investor Day on November 13

Goosehead Insurance, Inc. (NASDAQ: GSHD) announced it will host an Investor Day on Friday, November 13, 2026, at its Westlake headquarters. The event, starting at 10 a.m. EST, will feature presentations from the executive leadership team covering the company's vision, long-term growth plans, and …

ARWR6277444 Bond Risk Profile

This article provides a risk profile for the Arrowhead Pharmaceuticals, Inc. bond ARWR6277444, maturing on January 15, 2032. It highlights key metrics for credit risk assessment, including security level and issuer rating. The profile also mentions the availability of exclusive analyst ratings for bonds.

Is Arrowhead Pharmaceuticals (ARWR) Undervalued Or Is Its Pipeline Promise Already Priced In?

Arrowhead Pharmaceuticals (ARWR) has seen recent stock volatility, with a 4.1% gain in the past day but an 8.3% drop over the last month, yet a strong 1-year return. Analysts view the stock as undervalued with a fair value of $89.08 against its current …